In This Article:
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Eargo, Inc. (NASDAQ:EAR)
CONTACT JAKUBOWITZ ABOUT EAR:
https://claimyourloss.com/securities/eargo-inc-loss-submission-form/?id=20704&from=1
Class Period : October 16, 2020 - September 22, 2021
Lead Plaintiff Deadline : December 6, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Eargo had improperly sought reimbursements from certain third-party payors; (2) the foregoing was reasonably likely to lead to regulatory scrutiny; (3) as a result and because the reimbursements at issue involved the Company's largest third-party payor, Eargo's financial results would be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
CONTACT JAKUBOWITZ ABOUT BMRN:
https://claimyourloss.com/securities/biomarin-pharmaceutical-inc-loss-submission-form-2/?id=20704&from=1
Class Period : January 13, 2020 - September 3, 2021
Lead Plaintiff Deadline : December 22, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307 was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Reconnaissance Energy Africa Ltd. f/k/a Lund Enterprises Corp. (OTCQX:RECAF)
CONTACT JAKUBOWITZ ABOUT RECAF:
https://claimyourloss.com/securities/reconnaissance-energy-africa-ltd-f-k-a-lund-enterprises-corp-loss-submission-form/?id=20704&from=1
Class Period : February 28, 2019 - September 7, 2021
Lead Plaintiff Deadline : December 27, 2021